Skip to main content

Advertisement

Table 2 Synovial expression of CD markers and cytokines before and after treatment with infliximab

From: Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor

  Week 0 Week 9 P
CD3a 2 (0–3) 2 (0–2.5) Ns
CD68a 2.5 (1–3) 1 (0–2) 0.02
CD163a 1.5 (0–3) 1.5 (0–2) Ns
TNF mAb1 and mAb11a 0 (0–1) 0 (0–1) Ns
TNF 2C8b 0.25 (0–5.5) 0.3 (0–17.4) Ns
IFN-γa 1 (0–2) 0 (0–2) Ns
IL-1αb 0.9 (0.1–4.9) 1.2 (0.1–3.7) Ns
IL-1ßb 0.6 (0.1–7.3) 0.8 (0–33.1) Ns
IL-15 neutralizingb 2.7 (0.1–11.3) 2.8 (0–6.6) Ns
IL-15 non-neutralizingb 3.6 (0.4–16.7) 7.5 (0–15.1) Ns
  1. Synovial expression of CD markers (CD3 (T cells), CD68 (macrophages) and CD163 (fibroblasts)) and cytokines (IL-1a, IL-1ß, IL-15 neutralizing antibody, IL-15 non-neutralizing antibody, tumour necrosis factor (TNF; mAb1 and mAb11) and IFN-γ) was measured before treatment and after a median of 9 weeks of treatment with infliximab in patients with rheumatoid arthritis. aA semi-quantitative analysis was performed for the CD markers CD3, CD68 and CD163. Values are medians of the score for numbers of positive stained cells with ranges in parenthesis; a semi-quantitative four-point scale was used: 0 = no infiltration, 1 = minimal infiltration, 2 = moderate infiltration and 3 = marked infiltration. A semi-quantitative analysis of cytokines, TNF (mAb1 and mAb11) and IFN-γ was also performed. Values are medians of the score for numbers of positive stained cells, with ranges in parenthesis; a semi-quantitative four-point scale was used: 0 = no positive cells, 1 = 1 to 10 positive cells, 2 = 11 to 100 positive cells, and 3 = more than 100 positive cells. bA computerized image analysis was performed for IL-1α, IL-1ß, IL-15 neutralizing antibody and IL-15 non-neutralizing antibody; values are median percentages of the stained tissue area, with ranges in parenthesis. ns, not significant.